Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients

Abstract Classification of patients with rheumatoid arthritis (RA) as quickly as possible improves their prognosis. This reason motivates specially dedicated early arthritis (EA) clinics. Here, we have used 1062 EA patients with two years of follow-up to explore the value of anti-carbamylated protei...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cristina Regueiro, Laura Nuño, Ana M. Ortiz, Diana Peiteado, Alejandro Villalba, Dora Pascual-Salcedo, Ana Martínez-Feito, Isidoro González-Alvaro, Alejandro Balsa, Antonio González
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fc886adb586649bfb6a85851118c4f73
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc886adb586649bfb6a85851118c4f73
record_format	dspace
spelling	oai:doaj.org-article:fc886adb586649bfb6a85851118c4f732021-12-02T11:41:21ZValue of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients10.1038/s41598-017-09657-52045-2322https://doaj.org/article/fc886adb586649bfb6a85851118c4f732017-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09657-5https://doaj.org/toc/2045-2322Abstract Classification of patients with rheumatoid arthritis (RA) as quickly as possible improves their prognosis. This reason motivates specially dedicated early arthritis (EA) clinics. Here, we have used 1062 EA patients with two years of follow-up to explore the value of anti-carbamylated protein (anti-CarP) antibodies, a new type of RA specific autoantibodies, for classification. Specifically, we aimed to determine whether the addition of anti-CarP antibodies to IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are helpful in RA classification, improves it or not. Our analysis showed that incorporation of the anti-CarP antibodies to combinations of the other two antibodies (all joint by the OR Boolean operator) produces a modest increase in sensitivity (2.2% higher), at the cost of decreased specificity (8.1% lower). The cost-benefit ratio was more favorable in the patients lacking the other autoantibodies. However, it did not improve by considering different titer levels of the anti-CarP antibodies, or after exhaustively exploring other antibody combinations. Therefore, the place in RA classification of these antibodies is questionable in the context of current treatments and biomarkers. This conclusion does not exclude their potential value for stratifying patients in joint damage, disease activity, disability, or mortality categories.Cristina RegueiroLaura NuñoAna M. OrtizDiana PeiteadoAlejandro VillalbaDora Pascual-SalcedoAna Martínez-FeitoIsidoro González-AlvaroAlejandro BalsaAntonio GonzálezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Cristina Regueiro Laura Nuño Ana M. Ortiz Diana Peiteado Alejandro Villalba Dora Pascual-Salcedo Ana Martínez-Feito Isidoro González-Alvaro Alejandro Balsa Antonio González Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
description	Abstract Classification of patients with rheumatoid arthritis (RA) as quickly as possible improves their prognosis. This reason motivates specially dedicated early arthritis (EA) clinics. Here, we have used 1062 EA patients with two years of follow-up to explore the value of anti-carbamylated protein (anti-CarP) antibodies, a new type of RA specific autoantibodies, for classification. Specifically, we aimed to determine whether the addition of anti-CarP antibodies to IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are helpful in RA classification, improves it or not. Our analysis showed that incorporation of the anti-CarP antibodies to combinations of the other two antibodies (all joint by the OR Boolean operator) produces a modest increase in sensitivity (2.2% higher), at the cost of decreased specificity (8.1% lower). The cost-benefit ratio was more favorable in the patients lacking the other autoantibodies. However, it did not improve by considering different titer levels of the anti-CarP antibodies, or after exhaustively exploring other antibody combinations. Therefore, the place in RA classification of these antibodies is questionable in the context of current treatments and biomarkers. This conclusion does not exclude their potential value for stratifying patients in joint damage, disease activity, disability, or mortality categories.
format	article
author	Cristina Regueiro Laura Nuño Ana M. Ortiz Diana Peiteado Alejandro Villalba Dora Pascual-Salcedo Ana Martínez-Feito Isidoro González-Alvaro Alejandro Balsa Antonio González
author_facet	Cristina Regueiro Laura Nuño Ana M. Ortiz Diana Peiteado Alejandro Villalba Dora Pascual-Salcedo Ana Martínez-Feito Isidoro González-Alvaro Alejandro Balsa Antonio González
author_sort	Cristina Regueiro
title	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
title_short	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
title_full	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
title_fullStr	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
title_full_unstemmed	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients
title_sort	value of measuring anti-carbamylated protein antibodies for classification on early arthritis patients
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/fc886adb586649bfb6a85851118c4f73
work_keys_str_mv	AT cristinaregueiro valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT lauranuno valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT anamortiz valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT dianapeiteado valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT alejandrovillalba valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT dorapascualsalcedo valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT anamartinezfeito valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT isidorogonzalezalvaro valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT alejandrobalsa valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients AT antoniogonzalez valueofmeasuringanticarbamylatedproteinantibodiesforclassificationonearlyarthritispatients
_version_	1718395439649128448

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients

Ejemplares similares